Market Overview

Amgen Close to Buying Onyx Pharmaceuticals for $125/Share -NY TImes

Share:
Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen
Related AMGN
It's Not Shopping, It's Market Research: Talking Investing Trends With TD Ameritrade's Nicole Sherrod
The Other Bearish Biotech ETF Is Looking Groovy, Too
Can Top 10 Healthcare Dogs Average 25% Upsides And 27% Net Gains As Of September 2016? (Seeking Alpha)

The New York Times is reporting that Amgen (NASDAQ: AMGN) is close to a deal to acquire Onyx Pharmaceuticals (NASDAQ: ONXX) for $125 per share. The deal could be announced on Monday, according to sources.

Onyx rejected an offer of $120 per share from Amgen. Onyx Pharmaceuticals closed Friday at $116.96.

Posted-In: NY TimesNews Rumors M&A

 

Related Articles (AMGN + ONXX)

Get Benzinga's Newsletters